1. Home
  2. ADUS vs PHVS Comparison

ADUS vs PHVS Comparison

Compare ADUS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Addus HomeCare Corporation

ADUS

Addus HomeCare Corporation

N/A

Current Price

$114.53

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

N/A

Current Price

$31.49

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADUS
PHVS
Founded
1979
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
2.4B
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
ADUS
PHVS
Price
$114.53
$31.49
Analyst Decision
Buy
Strong Buy
Analyst Count
14
14
Target Price
★ $134.08
$57.49
AVG Volume (30 Days)
159.7K
★ 788.3K
Earning Date
11-02-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 23.40
N/A
EPS
★ 2.85
N/A
Revenue
N/A
N/A
Revenue This Year
$7.10
N/A
Revenue Next Year
$5.98
N/A
P/E Ratio
$40.09
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$87.95
$20.65
52 Week High
$124.44
$43.25

Technical Indicators

Market Signals
Indicator
ADUS
PHVS
Relative Strength Index (RSI) 49.03 38.06
Support Level $114.18 $24.95
Resistance Level $117.46 $36.36
Average True Range (ATR) 2.79 1.29
MACD 0.12 -0.17
Stochastic Oscillator 58.66 22.06

Price Performance

Historical Comparison
ADUS
PHVS

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: